Photosensitizing medications and photocarcinogenesis

Photodermatology Photoimmunology and Photomedicine

Volumn 30, Issue 1, 2014, Pages 8-14

  O'Gorman, Susan M ^a   Murphy, Gillian M ^a,b  

^a BEAUMONT HOSPITAL   (Ireland)

^b MATER MISERICORDIAE UNIVERSITY HOSPITAL   (Ireland)

Author keywords

Carcinogenesis; Genotoxicity; Medication; Photosensitization; Skin cancer

Indexed keywords

AZATHIOPRINE; BERGAPTEN; DIURETIC AGENT; DNA; FLEROXACIN; METHOXSALEN; PHOTOSENSITIZING AGENT; PSORALEN; QUINOLONE DERIVATIVE; TRIOXYSALEN; VORICONAZOLE;

BASAL CELL CARCINOMA; CANCER INCIDENCE; CANCER PATIENT; CARCINOGENESIS; DNA DAMAGE; DNA REPAIR; EPIDEMIOLOGICAL DATA; GENOTOXICITY; HIGH RISK PATIENT; HUMAN; NON MELANOMA SKIN CANCER; NONHUMAN; PHOTOALLERGY; PHOTOCARCINOGENESIS; PHOTOCHEMISTRY; PHOTOSENSITIVITY; PHOTOTOXICITY; PRIORITY JOURNAL; PSORIASIS; PUVA; REVIEW; RISK FACTOR; SQUAMOUS CELL CARCINOMA;

CARCINOGENESIS; GENOTOXICITY; MEDICATION; PHOTOSENSITIZATION; SKIN CANCER;

ANIMALS; CARCINOGENESIS; HUMANS; NEOPLASMS, RADIATION-INDUCED; PHOTOSENSITIZING AGENTS; SKIN NEOPLASMS;

EID: 84891825208     PISSN: 09054383     EISSN: 16000781     Source Type: Journal    
DOI: 10.1111/phpp.12085     Document Type: Review

References (62)

1. Melski JW, Tanenbaum L, Parrish JA, Fitzpatrick TB, Bleich HL. Oral methoxsalen photochemotherapy for the treatment of psoriasis: a cooperative clinical trial [Research Support, U.S. Gov't, Non-P.H.S.]. J Invest Dermatol 1977; 68: 328-335.
2. Weberschock T, Strametz R, Lorenz M etal. Interventions for mycosis fungoides [Meta-Analysis Research Support, Non-U.S. Gov't Review]. Cochrane Database Syst Rev 2012(9)CD008946.
3. Yones SS, Palmer RA, Garibaldinos TM, Hawk JL. Randomized double-blind trial of treatment of vitiligo: efficacy of psoralen-UV-A therapy vs Narrowband-UV-B therapy [Comparative Study Randomized Controlled Trial]. Arch Dermatol 2007; 143: 578-584.
4. Young AR, Magnus IA, Davies AC, Smith NP. A comparison of the phototumorigenic potential of 8-MOP and 5-MOP in hairless albino mice exposed to solar simulated radiation [Comparative Study Research Support, Non-U.S. Gov't]. Br J Dermatol 1983; 108: 507-518.
5. Gibbs NK, Young AR, Magnus IA. Failure of UVR dose reciprocity for skin tumorigenesis in hairless mice treated with 8-methoxypsoralen [Research Support, Non-U.S. Gov't]. Photochem Photobiol 1985; 42: 39-42.
6. Stern RS, Laird N, Melski J, Parrish JA, Fitzpatrick TB, Bleich HL. Cutaneous squamous-cell carcinoma in patients treated with PUVA [Research Support, U.S. Gov't, P.H.S.]. N Engl J Med 1984; 310: 1156-1161.
7. Stern RS, Laird N. The carcinogenic risk of treatments for severe psoriasis. Photochemotherapy Follow-up Study [Multicenter Study Research Support, U.S. Gov't, P.H.S.]. Cancer 1994; 73: 2759-2764.
8. Stern RS, Lange R. Non-melanoma skin cancer occurring in patients treated with PUVA five to ten years after first treatment [Research Support, U.S. Gov't, P.H.S.]. J Invest Dermatol 1988; 91: 120-124.
9. Stern RS, Nichols KT, Vakeva LH. Malignant melanoma in patients treated for psoriasis with methoxsalen (psoralen) and ultraviolet A radiation (PUVA). The PUVA Follow-Up Study [Multicenter Study Research Support, U.S. Gov't, P.H.S.]. N Engl J Med 1997; 336: 1041-1045.
10. Klecak G, Urbach F, Urwyler H. Fluoroquinolone antibacterials enhance UVA-induced skin tumors. J Photochem Photobiol B 1997; 37: 174-181.
11. Hannuksela-Svahn A, Pukkala E, Koulu L, Jansen CT, Karvonen J. Cancer incidence among Finnish psoriasis patients treated with 8-methoxypsoralen bath PUVA [Research Support, Non-U.S. Gov't]. J Am Acad Dermatol 1999; 40 (5 Pt 1): 694-696.
12. Hannuksela-Svahn A, Sigurgeirsson B, Pukkala E etal. Trioxsalen bath PUVA did not increase the risk of squamous cell skin carcinoma and cutaneous malignant melanoma in a joint analysis of 944 Swedish and Finnish patients with psoriasis [Research Support, Non-U.S. Gov't]. Br J Dermatol 1999; 141: 497-501.
13. Hannuksela A, Pukkala E, Hannuksela M, Karvonen J. Cancer incidence among Finnish patients with psoriasis treated with trioxsalen bath PUVA [Research Support, Non-U.S. Gov't]. J Am Acad Dermatol 1996; 35 (5 Pt 1): 685-689.
14. Lindelof B, Sigurgeirsson B, Tegner E, Larko O, Berne B. Comparison of the carcinogenic potential of trioxsalen bath PUVA and oral methoxsalen PUVA. A preliminary report [Comparative Study]. Arch Dermatol 1992; 128: 1341-1344.
15. Perrett CM, Walker SL, O'Donovan P etal. Azathioprine treatment photosensitizes human skin to ultraviolet A radiation. Br J Dermatol 2008; 159: 198-204.
16. Jensen P, Hansen S, Moller B etal. Skin cancer in kidney and heart transplant recipients and different long-term immunosuppressive therapy regimens [Research Support, Non-U.S. Gov't]. J Am Acad Dermatol 1999; 40 (2 Pt 1): 177-186.
17. Hartevelt MM, Bavinck JN, Kootte AM, Vermeer BJ, Vandenbroucke JP. Incidence of skin cancer after renal transplantation in the Netherlands. Transplantation 1990; 49: 506-509.
18. Molina BD, Leiro MG, Pulpon LA etal. Incidence and risk factors for nonmelanoma skin cancer after heart transplantation [Research Support, Non-U.S. Gov't]. Transplant Proc 2010; 42: 3001-3005.
19. Haylett AK, Felton S, Denning DW, Rhodes LE. Voriconazole-induced photosensitivity: photobiological assessment of a case series of 12 patients. Br J Dermatol 2013; 168: 179-185.
20. Walsh TJ, Anaissie EJ, Denning DW etal. Treatment of aspergillosis: clinical practice guidelines of the Infectious Diseases Society of America [Practice Guideline]. Clin Infect Dis 2008; 46: 327-360.
21. Vadnerkar A, Nguyen MH, Mitsani D etal. Voriconazole exposure and geographic location are independent risk factors for squamous cell carcinoma of the skin among lung transplant recipients [Research Support, N.I.H., Extramural]. J Heart Lung Transplant 2010; 29: 1240-1244.
22. Feist A, Lee R, Osborne S, Lane J, Yung G. Increased incidence of cutaneous squamous cell carcinoma in lung transplant recipients taking long-term voriconazole. J Heart Lung Transplant 2012; 31: 1177-1181.
23. Singer JP, Boker A, Metchnikoff C etal. High cumulative dose exposure to voriconazole is associated with cutaneous squamous cell carcinoma in lung transplant recipients [Research Support, N.I.H., Extramural Research Support, Non-U.S. Gov't Research Support, U.S. Gov't, P.H.S.]. J Heart Lung Transplant 2012; 31: 694-699.
24. Cowen EW, Nguyen JC, Miller DD etal. Chronic phototoxicity and aggressive squamous cell carcinoma of the skin in children and adults during treatment with voriconazole [Case Reports Multicenter Study Research Support, N.I.H., Intramural]. J Am Acad Dermatol 2010; 62: 31-37.
25. McLaughlin JM, Equils O, Somerville KT etal. Risk-adjusted relationship between voriconazole utilization and non-melanoma skin cancer among lung and heart/lung transplant patients. Transpl Infect Dis 2013; 15: 329-343.
26. Zwald FO, Spratt M, Lemos BD etal. Duration of voriconazole exposure: an independent risk factor for skin cancer after lung transplantation. Dermatol Surg 2012; 38: 1369-1374.
27. Miller DD, Cowen EW, Nguyen JC, McCalmont TH, Fox LP. Melanoma associated with long-term voriconazole therapy: a new manifestation of chronic photosensitivity [Case Reports]. Arch Dermatol 2010; 146: 300-304.
28. Johnson BE, Gibbs NK, Ferguson J. Quinolone antibiotic with potential to photosensitize skin tumorigenesis. J Photochem Photobiol B 1997; 37: 171-173.
29. Cadet J, Mouret S, Ravanat JL, Douki T. Photoinduced damage to cellular DNA: direct and photosensitized reactions [Review]. Photochem Photobiol 2012; 88: 1048-1065.
30. Stern RS, Bolshakov S, Nataraj AJ, Ananthaswamy HN. p53 mutation in nonmelanoma skin cancers occurring in psoralen ultraviolet a-treated patients: evidence for heterogeneity and field cancerization [Research Support, Non-U.S. Gov't Research Support, U.S. Gov't, P.H.S.]. J Invest Dermatol 2002; 119: 522-526.
31. Lhiaubet-Vallet V, Bosca F, Miranda MA. Photosensitized DNA damage: the case of fluoroquinolones [Research Support, Non-U.S. Gov't Review]. Photochem Photobiol 2009; 85: 861-868.
32. de Guidi G, Bracchitta G, Catalfo A. Photosensitization reactions of fluoroquinolones and their biological consequences [Review]. Photochem Photobiol 2011; 87: 1214-1229.
33. Traynor NJ, Gibbs NK. The phototumorigenic fluoroquinolone lomefloxacin photosensitizes pyrimidine dimer formation in human keratinocytes in vitro [Research Support, Non-U.S. Gov't]. Photochem Photobiol 1999; 70: 957-959.
34. Cadet J, Douki T, Ravanat JL, Di Mascio P. Sensitized formation of oxidatively generated damage to cellular DNA by UVA radiation [Research Support, Non-U.S. Gov't Review]. Photochem Photobiol Sci 2009; 8: 903-911.
35. Cadet J, Douki T, Ravanat JL. Oxidatively generated damage to the guanine moiety of DNA: mechanistic aspects and formation in cells [Review]. Acc Chem Res 2008; 41: 1075-1083.
36. Sauvaigo S, Douki T, Odin F, Caillat S, Ravanat JL, Cadet J. Analysis of fluoroquinolone-mediated photosensitization of 2′-deoxyguanosine, calf thymus and cellular DNA: determination of type-I, type-II and triplet-triplet energy transfer mechanism contribution. Photochem Photobiol 2001; 73: 230-237.
37. Marrot L, Belaidi JP, Jones C etal. Molecular responses to photogenotoxic stress induced by the antibiotic lomefloxacin in human skin cells: from DNA damage to apoptosis. J Invest Dermatol 2003; 121: 596-606.
38. O'Donovan P, Perrett CM, Zhang X etal. Azathioprine and UVA light generate mutagenic oxidative DNA damage [Research Support, Non-U.S. Gov't]. Science 2005; 309: 1871-1874.
39. Hofbauer GF, Attard NR, Harwood CA etal. Reversal of UVA skin photosensitivity and DNA damage in kidney transplant recipients by replacing azathioprine [Research Support, Non-U.S. Gov't]. Am J Transplant 2012; 12: 218-225.
40. Epaulard O, Leccia MT, Blanche S etal. Phototoxicity and photocarcinogenesis associated with voriconazole [Research Support, Non-U.S. Gov't Review]. Med Mal Infect 2011; 41: 639-645.
41. Murayama N, Imai N, Nakane T, Shimizu M, Yamazaki H. Roles of CYP3A4 and CYP2C19 in methyl hydroxylated and N-oxidized metabolite formation from voriconazole, a new anti-fungal agent, in human liver microsomes [Research Support, Non-U.S. Gov't]. Biochem Pharmacol 2007; 73: 2020-2026.
42. Yoshida Y, Aoyama Y. Interaction of azole antifungal agents with cytochrome P-45014DM purified from Saccharomyces cerevisiae microsomes [Research Support, Non-U.S. Gov't]. Biochem Pharmacol 1987; 36: 229-235.
43. Hitchcock CA, Dickinson K, Brown SB, Evans EG, Adams DJ. Interaction of azole antifungal antibiotics with cytochrome P-450-dependent 14 alpha-sterol demethylase purified from Candida albicans [Research Support, Non-U.S. Gov't]. Biochem J 1990; 266: 475-480.
44. Ikeda Y, Umemura K, Kondo K, Sekiguchi K, Miyoshi S, Nakashima M. Pharmacokinetics of voriconazole and cytochrome P450 2C19 genetic status [Comment Letter Research Support, Non-U.S. Gov't]. Clin Pharmacol Ther 2004; 75: 587-588.
45. Denning DW, Griffiths CE. Muco-cutaneous retinoid-effects and facial erythema related to the novel triazole antifungal agent voriconazole [Case Reports]. Clin Exp Dermatol 2001; 26: 648-653.
46. Flaherty KT, Puzanov I, Kim KB etal. Inhibition of mutated, activated BRAF in metastatic melanoma [Clinical Trial, Phase I Multicenter Study Research Support, Non-U.S. Gov't]. N Engl J Med 2010; 363: 809-819.
47. Dummer R, Rinderknecht J, Goldinger SM. Ultraviolet A and photosensitivity during vemurafenib therapy [Letter]. N Engl J Med 2012; 366: 480-481.
48. Gelot P, Dutartre H, Khammari A etal. Vemurafenib: an unusual UVA-induced photosensitivity [Letter]. Exp Dermatol 2013; 22: 297-298.
49. Anforth R, Tembe V, Blumetti T, Fernandez-Penas P. Mutational analysis of cutaneous squamous cell carcinomas and verrucal keratosis in patients taking BRAF inhibitors [Research Support, Non-U.S. Gov't]. Pigment Cell Melanoma Res 2012; 25: 569-572.
50. Su F, Viros A, Milagre C etal. RAS mutations in cutaneous squamous-cell carcinomas in patients treated with BRAF inhibitors [Clinical Trial, Phase I Clinical Trial, Phase II Clinical Trial, Phase III Research Support, Non-U.S. Gov't]. N Engl J Med 2012; 366: 207-215.
51. Oberholzer PA, Kee D, Dziunycz P etal. RAS mutations are associated with the development of cutaneous squamous cell tumors in patients treated with RAF inhibitors [Research Support, N.I.H., Extramural Research Support, Non-U.S. Gov't]. J Clin Oncol 2012; 30: 316-321.
52. Jensen AO, Thomsen HF, Engebjerg MC, Olesen AB, Sorensen HT, Karagas MR. Use of photosensitising diuretics and risk of skin cancer: a population-based case-control study [Research Support, N.I.H., Extramural Research Support, Non-U.S. Gov't]. Br J Cancer 2008; 99: 1522-1528.
53. Davis R, Wells CH, Taylor AR. Photolytic decomposition of indapamide. J Pharm Sci 1979; 68: 1063-1064.
54. Larue L, Dougherty N, Mintz B. Genetic predisposition of transgenic mouse melanocytes to melanoma results in malignant melanoma after exposure to a low ultraviolet B intensity nontumorigenic for normal melanocytes [Research Support, Non-U.S. Gov't Research Support, U.S. Gov't, P.H.S.]. Proc Natl Acad Sci U S A 1992; 89: 9534-9538.
55. Kaae J, Boyd HA, Hansen AV, Wulf HC, Wohlfahrt J, Melbye M. Photosensitizing medication use and risk of skin cancer [Research Support, Non-U.S. Gov't]. Cancer Epidemiol Biomarkers Prev 2010; 19: 2942-2949.
56. Robinson SN, Zens MS, Perry AE, Spencer SK, Duell EJ, Karagas MR. Photosensitizing agents and the risk of non-melanoma skin cancer: a population-based case-control study. J Invest Dermatol 2013; 133: 1950-1955.
57. Gallagher RP, Hill GB, Bajdik CD etal. Sunlight exposure, pigmentary factors, and risk of nonmelanocytic skin cancer. I. Basal cell carcinoma [Research Support, Non-U.S. Gov't]. Arch Dermatol 1995; 131: 157-163.
58. Lynch AM, Guzzie PJ, Bauer D etal. Considerations on photochemical genotoxicity. II: report of the 2009 International Workshop on Genotoxicity Testing Working Group. Mutat Res 2011; 723: 91-100.
59. EMA, CPMP/SWP/398/01 'Note for Guidance on Photosafety Testing', London, 2002.
60. FDA/CDER Guidance for Industry. Photosafety testing, 2003.
61. Note 1. ICH guideline S10: Guidance on photosafety evaluation of pharmaceuticals, EMA/CHMP/ICH/752211/2012.
62. Bech-Thomsen N, Wulf HC. Sunbathers' application of sunscreen is probably inadequate to obtain the sun protection factor assigned to the preparation. Photodermatol Photoimmunol Photomed 1992; 9: 242-244.